Tcr2 Therapeutics Inc (TCRR) Director Morana Jovan-Embiricos Acquires 666,667 Shares of Stock

Share on StockTwits

Tcr2 Therapeutics Inc (NASDAQ:TCRR) Director Morana Jovan-Embiricos purchased 666,667 shares of the company’s stock in a transaction dated Tuesday, February 19th. The stock was bought at an average price of $15.00 per share, with a total value of $10,000,005.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of TCRR stock traded up $0.06 during trading hours on Friday, reaching $15.19. The company had a trading volume of 807 shares, compared to its average volume of 165,848.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Macon Daily and is owned by of Macon Daily. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://macondaily.com/2019/02/22/tcr2-therapeutics-inc-tcrr-director-morana-jovan-embiricos-acquires-666667-shares-of-stock.html.

About Tcr2 Therapeutics

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Further Reading: Net Asset Value

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.